end of the downside- back in, page-78

Do they really need another capital raise that soon? Raised $5m in recent months, adding to the $10m cash pile as at end of March quarter. Cash burn in FY18, when they weren't running any clinical trials, was around $6m. For comparison, cash burn in FY19 was $14m but they conducted a phase 1 trial during that period.

Assuming the FY18 net cash burn rate ($6m annualised) is more representative for the near term of say, next 6 months, since we aren't expecting trials to be conducted in the near term, seems like their cash pile is more than enough to tide them through that period?